Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
ITHACA, N.Y., April 17, 2018 -- Early graft failure after CABG surgery, due to vessel defects, anastomotic technical errors, poor native run-off or competitive flow, is reported in up to 12 percent of grafts. This can result in reoperations and readmissions – undesirable outcomes for patients and hospitals. Transonic’s newest flowmeter, the 354C Optima, incorporates decades of expertise in flow measurement, waveform morphology and the development of flow assessment algorithms to simplify graft patency assessment during coronary artery bypass grafting surgery (CABG). A short 8-second snapshot of patient flow and pressure data will trigger an analysis of this data based on the company’s CABG flow assessment protocol, and report its findings.
Transonic believes that Interoperative flow measurement together with our CABG patency assessment protocol will improve outcomes, reduce the incidence of re-interventions and readmissions, and contribute to hospital quality goals. Transonic is so confident in the value of this measurement that it will collaborate with hospitals in pursuit of their strategic quality improvement initiatives to reduce preventable readmissions, that it will offer credit for future meter use should a patient be readmitted within 30 days.
Per Transonic’s CEO Cor Drost: “We introduced ultrasound transit-time flowmetry during the early days of beating heart CABG surgery, and developed flow-based graft patency algorithms together with our collaborator Dr. Bruce Mindich. These algorithms have withstood the test of time, and are now incorporated in our flowmeter in a manner where flow-based CABG patency assessment may become part of the routine armamentarium of all CABG surgeons.”
For over three decades, Transonic Systems, pioneer of transit-time ultrasound technology for volume flow measurement, has led the world in advancing meaningful measurements for biomedical applications. The Optima 354C takes this measurement know-how one step further to assist cardiac surgeons as they make surgical decisions.
To learn more about this innovative partnership program visit our website.
Contact: Miriam Tenorio, Vice President, Marketing: 607-257-5300
